Stoke Therapeutics, Inc. STOK Accrued investment income
Accrued investment income at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:InterestReceivableCurrent.
The official record: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Stoke Therapeutics, Inc.'s accrued investment income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Stoke Therapeutics, Inc.'s accrued investment income?
- Stoke Therapeutics, Inc. (STOK) reported accrued investment income of $1.69M in Q1 2026.
- How has Stoke Therapeutics, Inc.'s accrued investment income changed year-over-year?
- Stoke Therapeutics, Inc.'s accrued investment income increased by 178.9% year-over-year, from $606K to $1.69M.
- What is the long-term trend for Stoke Therapeutics, Inc.'s accrued investment income?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s accrued investment income has grown at a 218.6% compound annual growth rate (CAGR), from $6K to $1.97M.
- What does accrued investment income mean?
- This represents interest or dividend income that has been earned by the company's investment portfolio but has not yet been collected in cash as of the balance sheet date. It reflects the accrual of returns on cash equivalents and marketable securities, providing insight into the yield generated by the company's treasury management. Monitoring this balance helps investors understand the timing of cash inflows from non-operating financial assets.